White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
Seach Medical Group Ltd (SEMG) currently trades at 2.65 ILS, while our model-based Fair Value estimate is 5.26 ILS, implying the stock looks roughly 50% undervalued today.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (0.0115 ILS per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income
1.70 ILS
1.74 ILS
1.83 ILS
74
FCF DCF
7.81 ILS
11.62 ILS
23.24 ILS
72
Growth DCF
7.34 ILS
13.16 ILS
22.41 ILS
71
All 26 models by family
DCF Models
FCF DCF
7.81 ILS
11.62 ILS
23.24 ILS
72
Owner Earnings
3.46 ILS
7.15 ILS
14.33 ILS
66
5Y Revenue Exit
5.49 ILS
8.93 ILS
16.09 ILS
65
5Y EBITDA Exit
6.64 ILS
11.25 ILS
20.28 ILS
67
5Y P/E Exit
3.07 ILS
4.75 ILS
6.74 ILS
66
10Y Revenue Exit
6.13 ILS
12.17 ILS
15.72 ILS
62
10Y EBITDA Exit
7.08 ILS
14.52 ILS
27.18 ILS
60
10Y P/E Exit
4.60 ILS
7.20 ILS
10.79 ILS
59
Earnings-Based
Graham-Dodd
0.3100 ILS
2.18 ILS
3.06 ILS
61
Lynch FV
1.21 ILS
1.73 ILS
2.25 ILS
59
PEG = 1.0
1.21 ILS
1.73 ILS
2.25 ILS
55
EPV
2.96 ILS
3.36 ILS
3.70 ILS
70
Dividend Discount
Gordon GGM
1.00 ILS
1.90 ILS
2.75 ILS
65
DDM Multi-Stage
1.00 ILS
1.68 ILS
2.02 ILS
65
Multiples
P/E Multiple
0.7600 ILS
1.01 ILS
1.27 ILS
63
P/S Multiple
0.5900 ILS
0.7800 ILS
0.9800 ILS
58
P/B Multiple
7.63 ILS
10.18 ILS
12.72 ILS
55
EV/EBIT
5.15 ILS
6.96 ILS
8.76 ILS
63
EV/EBITDA
5.48 ILS
7.39 ILS
9.30 ILS
64
EV/Revenue
3.60 ILS
5.26 ILS
6.92 ILS
51
Asset-Based
NCAV (Graham)
0.9600 ILS
1.46 ILS
1.83 ILS
52
Growth DCF
Growth DCF
7.34 ILS
13.16 ILS
22.41 ILS
71
Rev-Margin DCF
6.02 ILS
10.19 ILS
18.94 ILS
65
Economic Profit
Residual Income
1.70 ILS
1.74 ILS
1.83 ILS
74
ROIC Compounder
3.27 ILS
4.34 ILS
5.31 ILS
68
Growth Earnings
Growth-Adj P/E
1.50 ILS
2.14 ILS
2.78 ILS
65
Open the full fair value analysis →
Overall quality
64/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
41
How much profit the company makes from its sales and capital
Quality Growth
17
Are margins and returns getting better?
Cashflow
73
Do the profits arrive as real cash?
Financial strength
72
Debt, balance sheet and risk of trouble
Investment
98
Does it invest with discipline instead of growing at any price?
Low Volatility
67
How calm the share price moves, does not count
Price momentum
45
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high
47
Distance to the 52-week high, does not count
New shares
93
Buys back shares or issues new ones?
Open the full quality analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is Seach Medical Group Ltd (SEMG) overvalued or undervalued?
As of Nov 17, 2026, our model estimates a fair value of 5.26 ILS versus a price of 2.65 ILS, about +99% upside (undervalued).
What is the fair value of SEMG?
Our model-based fair value for Seach Medical Group Ltd is 5.26 ILS (as of Nov 17, 2026), built from audited fundamentals. The current price: 2.65 ILS.
What is the quality score of SEMG?
Seach Medical Group Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Seach Medical Group Ltd (SEMG)?
We do not set a price target; the yardstick is the fair value of 5.26 ILS (as of Nov 17, 2026) from 26 valuation models. Cautious scenario 3.60 ILS, optimistic scenario 6.92 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the Seach Medical Group Ltd stock forecast for 2026?
Our models put fair value at 5.26 ILS, about +99% upside versus a price of 2.65 ILS (undervalued). Cautious scenario 3.60 ILS, optimistic scenario 6.92 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of Seach Medical Group Ltd (SEMG)?
Seach Medical Group Ltd reported trailing-twelve-month revenue of about 154M ILS (latest available figure, as of Nov 17, 2026).
Does Seach Medical Group Ltd pay a dividend?
Seach Medical Group Ltd currently shows a dividend yield of 6.79% relative to its recent price (as of Nov 17, 2026).
How much is the dividend of Seach Medical Group Ltd (SEMG) and when is the ex-dividend date?
Seach Medical Group Ltd pays a dividend of 0.18 ILS per share a year, a dividend yield of 6.8%. The last ex-dividend date was Apr 9, 2026. The payout ratio is 93.3% of earnings. Free cash flow covers the dividend 2.60 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Seach Medical Group Ltd (SEMG)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Seach Medical Group Ltd shrinks by 19.7 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 33.7 % per year. As of Nov 17, 2026.
What discount rate (WACC) does the fair value of SEMG use?
Our models discount Seach Medical Group Ltd at 10.1 %: a base by market capitalisation (nano), damped by beta 0.25, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Seach Medical Group Ltd that is -19.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Seach Medical Group Ltd (SEMG) delivered so far?
Over the past 5 years revenue at Seach Medical Group Ltd grew 33.7 % a year. The price currently implies free-cash-flow growth of -19.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Seach Medical Group Ltd (SEMG) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Seach Medical Group Ltd (-19.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Seach Medical Group Ltd (SEMG)?
The free-cash-flow yield on the price is 17.68 %: that much free cash flow Seach Medical Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Seach Medical Group Ltd (SEMG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Seach Medical Group Ltd it is 5.26 ILS per share (as of Nov 17, 2026), against a price of 2.65 ILS. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Seach Medical Group Ltd stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SEMG trades below its calculated fair value: price 2.65 ILS, fair value 5.26 ILS, a gap of about +99% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SEMG?
No. The price is what the market pays today (2.65 ILS); the fair value is what the company's own numbers justify (5.26 ILS). For Seach Medical Group Ltd the two are 2.61 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Seach Medical Group Ltd worth?
The market values Seach Medical Group Ltd at about 87.7M ILS (market capitalisation, as of Nov 17, 2026). Per share that is 2.65 ILS; our models calculate a fair value of 5.26 ILS per share.
What do the bullish and bearish scenarios say about SEMG?
Our models span a range for Seach Medical Group Ltd: cautious scenario 3.60 ILS, base 5.26 ILS, optimistic 6.92 ILS per share (as of Nov 17, 2026, price 2.65 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SEMG?
Seach Medical Group Ltd trades at a price-to-earnings ratio of 13.7 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5.26 ILS is built from several models across several years. Other multiples: P/B 1.0, P/S 0.6, EV/EBITDA 4.3.
How solid is the balance sheet of Seach Medical Group Ltd (SEMG)?
Balance-sheet figures for Seach Medical Group Ltd (as of Nov 17, 2026): return on equity 5.5%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is SEMG from its 52-week high?
Seach Medical Group Ltd trades at 2.65 ILS, about 16% below its 52-week high of 3.14 ILS and 23% above the low of 2.15 ILS (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 5.26 ILS is for.
Which stocks are comparable to Seach Medical Group Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Seach Medical Group Ltd stock attractive at the current price?
The data as of Nov 17, 2026: price 2.65 ILS, calculated fair value 5.26 ILS (+99%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SEMG calculated?
We run Seach Medical Group Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5.26 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Seach Medical Group Ltd currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of Seach Medical Group Ltd (SEMG)?
The closing price on Nov 19, 2026 was 2.65 ILS. Our model-based fair value is 5.26 ILS, about +99% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Seach Medical Group Ltd right now?
The price is below even our cautious bear case (3.60 ILS). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (3.60 ILS to 6.92 ILS) leaves room in how you read the outcome.
Key figures of Seach Medical Group Ltd
How large is the market capitalisation of Seach Medical Group Ltd (SEMG)?
The market capitalisation of Seach Medical Group Ltd is 87.7M ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Seach Medical Group Ltd (SEMG)?
The price-to-sales ratio of Seach Medical Group Ltd is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Seach Medical Group Ltd (SEMG)?
Earnings per share at Seach Medical Group Ltd are 0.1930 ILS (price ÷ EPS = P/E 13.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Seach Medical Group Ltd (SEMG)?
The dividend yield of Seach Medical Group Ltd is 6.8% (payout 93.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Seach Medical Group Ltd (SEMG)?
The net margin of Seach Medical Group Ltd is 4.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Seach Medical Group Ltd (SEMG)?
The return on equity (ROE) of Seach Medical Group Ltd is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Seach Medical Group Ltd (SEMG)?
On an EBIT basis the return on assets of Seach Medical Group Ltd is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Seach Medical Group Ltd (SEMG)?
The operating margin of Seach Medical Group Ltd is 16.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Seach Medical Group Ltd (SEMG)?
Revenue at Seach Medical Group Ltd is down 7.3% versus a year earlier (3y avg +5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Seach Medical Group Ltd (SEMG)?
Earnings per share at Seach Medical Group Ltd are growing 44.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Seach Medical Group Ltd (SEMG) carry?
The net debt of Seach Medical Group Ltd is 8.7M ILS (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.